These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30719631)

  • 21. The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
    Scarpa D; Denas G; Babuin L; Pengo V
    Expert Opin Pharmacother; 2019 Feb; 20(3):261-268. PubMed ID: 30615495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
    Cave B; Hough A; Dobesh PP
    Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.
    Ageno W
    Intern Emerg Med; 2018 Oct; 13(7):1009-1013. PubMed ID: 28808888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
    Dobesh PP; Trevarrow BJ
    Am J Med; 2019 Mar; 132(3):307-311. PubMed ID: 30201249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
    Chi G; Goldhaber SZ; Hull RD; Hernandez AF; Kerneis M; Al Khalfan F; Cohen AT; Harrington RA; Gibson CM
    Thromb Haemost; 2017 Dec; 117(12):2389-2395. PubMed ID: 29212126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
    Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ
    Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
    Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA
    Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
    Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
    Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
    Jamil A; Jamil U; Singh K; Khan F; Chi G
    Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.
    Guy H; Laskier V; Fisher M; Bucior I; Deitelzweig S; Cohen AT
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):259-267. PubMed ID: 31215264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
    Liew AY; Piran S; Eikelboom JW; Douketis JD
    J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the oral direct factor Xa inhibitor - betrixaban.
    Palladino M; Merli G; Thomson L
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1465-72. PubMed ID: 23964817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Betrixaban in the prevention of venous thromboembolism in medically ill patients.
    Sylvester KW; Connors JM
    Future Cardiol; 2018 Nov; 14(6):455-470. PubMed ID: 30353749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Mebazaa A; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Merli G; Schellong SW; Spyropoulos AC; Tapson VF; De Sanctis Y; Cohen AT
    Circulation; 2014 Jul; 130(5):410-8. PubMed ID: 24970782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
    Arbetter DF; Jain P; Yee MK; Michalak N; Hernandez AF; Hull RD; Goldhaber SZ; Harrington RA; Gold A; Cohen AT; Gibson CM
    Pharm Stat; 2017 Nov; 16(6):445-450. PubMed ID: 28840662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.